These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28746882)

  • 1. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
    Anderson GR; Winter PS; Lin KH; Nussbaum DP; Cakir M; Stein EM; Soderquist RS; Crawford L; Leeds JC; Newcomb R; Stepp P; Yip C; Wardell SE; Tingley JP; Ali M; Xu M; Ryan M; McCall SJ; McRee AJ; Counter CM; Der CJ; Wood KC
    Cell Rep; 2017 Jul; 20(4):999-1015. PubMed ID: 28746882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
    Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
    Cheon SK; Kim HP; Park YL; Jang JE; Lim Y; Song SH; Han SW; Kim TY
    Mol Oncol; 2018 Aug; 12(8):1398-1409. PubMed ID: 29896883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Safe Soluble Compound Dehydroascorbic Acid Inhibits Various Upstream and Downstream Effectors of PI3K and KRAS Signaling Pathways in Undruggable
    Kalbkhani F; Pirnejad A; Sam S; Sam MR
    Nutr Cancer; 2021; 73(11-12):2654-2664. PubMed ID: 33283545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR and KRAS: a match yet to be made.
    Bender G; Fahrioglu Yamaci R; Taneri B
    J Biomed Sci; 2021 Nov; 28(1):77. PubMed ID: 34781949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.
    Yau EH; Kummetha IR; Lichinchi G; Tang R; Zhang Y; Rana TM
    Cancer Res; 2017 Nov; 77(22):6330-6339. PubMed ID: 28954733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
    Dompe N; Klijn C; Watson SA; Leng K; Port J; Cuellar T; Watanabe C; Haley B; Neve R; Evangelista M; Stokoe D
    PLoS One; 2018; 13(6):e0199264. PubMed ID: 29912950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Ziemke EK; Dosch JS; Maust JD; Shettigar A; Sen A; Welling TH; Hardiman KM; Sebolt-Leopold JS
    Clin Cancer Res; 2016 Jan; 22(2):405-14. PubMed ID: 26369631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting metabolic reprogramming in KRAS-driven cancers.
    Kawada K; Toda K; Sakai Y
    Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.